Use of thiazolidinediones and risk of hospitalization for myocardial infarction with type 2 diabetes
碩士 === 國立陽明大學 === 衛生福利研究所 === 97 === Background: Thiazolidinediones (TZDs) are new class of oral antidiabetic agents, however, recent studies have raised concerns over the increased cardiovascular (CV) risk of TZDs in type 2 diabetic patients. Aim: To assess the risk of myocardial infarction (MI) in...
Main Authors: | Shu-Ting Chan, 詹婌婷 |
---|---|
Other Authors: | Weng-Foung Huang |
Format: | Others |
Language: | zh-TW |
Published: |
2009
|
Online Access: | http://ndltd.ncl.edu.tw/handle/30436748322885484311 |
Similar Items
-
Thiazolidinedione and cardiovascular risk in type 2 diabetes mellitus
by: Yenny Yenny
Published: (2016-04-01) -
Redefining the role of thiazolidinediones in the management of type 2 diabetes
by: Anthony H Barnett
Published: (2009-01-01) -
Appropriateness of the use of Thiazolidinediones for the treatment of Type 2 Diabetes Mellitus at the Southern Arizona Veterans Affairs Hospital
by: Fletcher, Glory, et al.
Published: (2005) -
Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes
by: John M Stafford, et al.
Published: (2007-09-01) -
Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes
by: John M Stafford, et al.
Published: (2007-10-01)